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Background: On the back of its recent economic development and domestic success in the fight against HIV/AIDS,
Brazil is helping the Government of Mozambique to set up a pharmaceutical factory as part of its South-South
cooperation programme. Until recently, a consensus existed that pharmaceutical production in Africa was not viable
or sustainable. This paper looks into practicalities and evolution of this collaboration to illustrate the characteristics
of Brazilian development cooperation in health, with the aim of drawing lessons for the wider debate on aid and
local production of pharmaceuticals in Africa.
Discussion: We show that the project process has been very long and complex, has involved multiple public and
private partners, and cost in excess of USD34 million. There have also been setbacks in the process, and although
production has already started, it is unclear whether all the project’s original objectives will be met.
Summary: The Brazil-Mozambique’s pharmaceutical factory experience illustrates positives as well as limitations of
Brazil’s unorthodox approach to health development cooperation, highlighting its contribution to pushing the
boundaries of the debate on local production of pharmaceuticals in resource-poor settings.
Keywords: AIDS, Pharmaceutical production, Aid architecture in health, Brazil pharmaceuticals, ARV, Manufacturing
in Africa, Aid effectiveness in healthBackground
On the back of its economic growth, newly acquired inter-
national standing and domestic public health record,
Brazil has set out to expand its South-South cooperation
in the health sector and in the specific field of HIV/AIDS
[1]. Like other emerging donors, Brazil has not yet come
to define a comprehensive development cooperation pol-
icy, nor does it subscribe to the principles of aid effective-
ness [2,3]. This grants Brazil and other emerging donors
unprecedented flexibility in the interpretation of their co-
operation programmes, allowing for out-of-the-box think-
ing on modalities and features of their cooperation projects
in comparison to traditional donors [4].* Correspondence: grusso@ihmt.unl.pt
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unless otherwise stated.In their support for access to medicines in African
countries, traditional donors have given priority to global
purchasing and distribution initiatives rather than to do-
mestic production. They have tended to subscribe to the
consensus that African pharmaceutical factories would
not be able to produce quality pharmaceuticals at com-
petitive prices [5]. However, the African socio economic
climate is rapidly changing because of the discovery of
additional natural resources, changing geopolitical influ-
ences, and maturing demographic dividends [6]. Brazil is
taking advantage of this context to expand its foreign
and global health policy influence by undertaking bilat-
eral cooperation projects with those countries and in
those domains where it enjoys a competitive advantage,
implementing a so-called ‘health diplomacy’ [7,8]. As part of
this process, it is helping the government of Mozambique to
set up a publicly-owned pharmaceutical factory in the out-
skirts of the capital city Maputo; this will also produce
Antiretrovirals (ARVs), inspired by Brazil’s domestic
success in the fight against HIV/AIDS, its beliefs on thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Russo et al. Globalization and Health 2014, 10:70 Page 2 of 8
http://www.globalizationandhealth.com/content/10/1/70connection between a country’s industrial growth and its
health system development, and by strongly-held princi-
ples of economic self-reliance and state capitalism.
HIV/AIDS prevalence in Mozambique is currently es-
timated at 11.5% among the adult population [8]; Anti-
retroviral treatment was introduced in 2003 and rapidly
scaled up with the support of international initiatives [9].
In 2011 an estimated 273,501 patients were receiving
ARV treatment, approximately 45.5% of those needing
it, and the Ministry of Health of Mozambique (MISAU)
is currently planning on scaling-up ART to cover 80% of
those suitable for treatment [10]. In 2012 approximately
USD 66 Million worth of HIV/AIDS drugs were distributed
through the public health care system, procured, funded
and imported by international structures such as the Clin-
ton Health Access Initiative (CHAI/UNITAID), USAID’s
Global HIV/AIDS Programme (GAP), the UN Global Fund
(GF R09/VPP), USAID’s Supply Chain Management
Systems (USG/SCMS), and USAID’s HIV/AIDS Clinical
Services Project. These structures procure the drugs though
large annual international tenders (Figure 1).
The Government of Mozambique (GoM) currently does
not contribute directly to financing and acquisition of
ARVs, although all the drugs are distributed through the
distribution system of MISAU’s Medicines and Medical
Supplies Central Services. ARV drugs in 2012 represented
56% of the country’s public drug bill [11].
The present paper looks at innovative features, achieve-
ments and setbacks of the Brazil-Mozambique collabor-
ation to produce essential medicines in Africa, with the
objective of contributing to the debate on health aidFigure 1 Mozambique’s annual ARV imports, per funding agency (20modalities and local production of pharmaceuticals in low-
and middle-income countries (LMIC). This work is based
on the authors’ first-hand experience of the process of set-
ting up the factory, on the review of diplomatic agreements
and business reports, and on interviews with Brazilian and
Mozambican government officials, members of the inter-
national aid community and pharmaceutical industry in
Mozambique. Ethical approval was granted by the Instituto
de Higiene e Medicina Tropical’s Ethics Committee, and
informed written consent was obtained by the people
interviewed.
Discussion
The Brazilian approach to health cooperation and
pharmaceutical production
Until very recently a net aid recipient, Brazil’s cooperation
programme in 2010 was estimated to be worth USD 923
million between contributions to international organisa-
tions and technical projects [12], with Mozambique as its
single largest recipient country [13]. With a geographic
focus on Latin America and Portuguese-speaking African
countries and typically lacking grant components, Brazilian
technical cooperation in health is claimed to be inspired by
a set of core principles, including reciprocal ‘horizontal
cooperation’ between LMICs free of traditional aid
conditionalities [14], promotion of the local healthcare in-
dustry as a way to spur national health system growth and
evolution – described as the development of a ‘health in-
dustrial complex’ [15] –, ‘health diplomacy’ or mutual in-
fluence of global health and foreign policy objectives [16],
and ‘structuring cooperation’ , a form of action aimed at12 USD).
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tions and people that served in Brazil’s own experience as
catalysts for health systems development [17].
Brazil’s position on HIV/AIDS drugs appears in line
with its support to strong Government involvement in
the provision of health care services [18], underpinned
by a Constitutional framework that establishes a univer-
sal citizen right to health and places a duty of health
care provision on the state. The growing roles of the
Ministry of Health research and training agency Fundação
Oswaldo Cruz (Fiocruz) and its pharmaceutical arm Farm-
anguinhos – influential Government institutions behind
the development of the ARV industry in Brazil – are ex-
emplifications of the strength of this paradigm of state-led
health development [19]. According to a 2008 count,
Brazil’s national pharmaceutical industry included 18 pub-
lic pharmaceutical labs - 8 of which registered to produce
ARVs - although publicly-produced drugs only repre-
sented around 5% of the total national pharmaceutical
market value, and 25% of the ARVs one [20].
In its approach to pharmaceutical production Brazil rep-
resents a notable challenge to the prevailing arguments on
Trade-Related Intellectual Property Rights (TRIPS) and
local production of pharmaceuticals. In 2006 two conflict-
ing pieces of legislation were passed in Brazil, one guaran-
teeing free access to ARVs, and the other hampering the
domestic production of cheap ARVs [21]. The Sarney
Lawa (9313/96) aimed at guaranteeing HIV/AIDS patients
the right to be treated, paving the way to scaling-up ARV
treatment in the country. The same year a new national
Intellectual Property Law (9279/96) sanctioned the
government obligation to grant patents to protect pharma-
ceutical companies’ right to exclusively manufacture regis-
tered drugs, limiting the possibility for local laboratories to
produce lower-cost versions of ARVs under patent [22].
Through subsequent legislation, Brazil also incorporated in
its patent law the TRIPS flexibilities to mitigate the effects
of patents regime in developing countries, notably compul-
sory licensing, experimental and bolear exemptions, parallel
imports and government participation in patent application
processb. Between 2001 and 2007, Brazil made use of the
above flexibilities to obtain substantial price reductions for
patented ARVs, and in the case of Efavirenz, to issue com-
pulsory licensing [20]. Brazil is also one of the founding
members, key advocate and supporter of UNITAID, an in-
novative patent pool mechanism granting licenses to pro-
duce drugs in developing countries against the payment
of royalties [23]. Since 2012 Brazil has also engaged in
Productive Development Partnerships with international
manufactures, where production and technology of pat-
ented pharmaceuticals are transferred to public laborator-
ies in exchange of the right to exclusive supply of these
drugs to the Unified Health Care System at negotiated
prices for an agreed time-span [24].The debate on production of pharmaceuticals in Africa
The issue of local production of medicines is complex
and often muddled by conflicting public health and in-
dustrial policy agendas [25]. Until recently, a consensus
existed that Africa-based industry would not be able to
produce quality pharmaceuticals at competitive prices,
and that a local critical mass of industrial and socio-
economic development was required to allow the industry
to survive [5]. Some authors pointed out that promoting
local pharmaceutical production was unlikely to bring
down high medicine prices, particularly for on-patent
ARVs, as these were mostly determined by international
Intellectual Property Rights rather than by local manufac-
turing costs [26].
These views notwithstanding, numerous pharmaceut-
ical factories have started operations in Africa, and 38
countries in the continent are at present estimated to
have pharmaceutical manufacturing entities [27]. North
African countries and South Africa are reported to be
home to the largest and most sophisticated factories in
the continent, while smaller but still significant pharma-
ceutical production facilities are to be found in Ethiopia,
Nigeria, Kenya, Uganda and Zimbabwe [27-31]. The ma-
jority of pharmaceutical manufacturers in Africa are re-
ported to be small private companies primarily serving the
local market, although larger publicly owned enterprises
are also being establishedc. International importers and
distributors are also setting up their own plants in the
continent or entering joint ventures with local manufac-
turersd [28].
As a sign of change, United Nations and African Union
agencies have started projects to study the arguments and
evidence around local production of medicines [32]. Re-
cent work on the subject has showed that the evidence
around the supposedly high prices of locally produced
medicines is at best mixed [33,34]. Some take the view
that positions may be shifting around local pharmaceutical
production because of the increase in demand for medi-
cines from the developing world coupled with increased
availability of funding (especially for HIV/AIDS drugs), as
well as because of the recent changes in patent rules.
Brazil-Mozambique collaboration for the production of
pharmaceuticals
The idea of a Brazil-Mozambique cooperation project to
set up the first public pharmaceutical factory in Africa
was agreed between the former respective presidents
Luiz Inácio Lula da Silva and Joaquim Chissano in 2003,
developed within Brazil’s nascent approach to ‘South-
South’ cooperation in the health sector, and surviving
changes of governments in Brazil as in Mozambique [3].
The initiative to set up a pharmaceutical factory in
Mozambique initially had the following stated objectives:
(a) to secure the ARV supply for HIV/AIDS treatment in
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manufacturing in Mozambique, enabling the fulfilment of
the objectives of the national Primary Care and Pharma-
ceutical policies; (c) to reduce the country’s dependence
on pharmaceutical donations and imports, and; (d) to con-
tribute to the creation of local capacity for pharmaceutical
production and industrial management [35]. The original
cooperation agreement stated that the Government of
Brazil (GoB) was going to take responsibility for the pro-
ject’s staff training, for procuring equipment and raw ma-
terials, for providing technical assistance, and for
designing the factory and managing the project. The Gov-
ernment of Mozambique would have been responsible for
purchasing the physical infrastructure for the factory, for
undertaking rehabilitation works, for funding the factory’s
recurrent expenditures, and for buying the bulk of the
factory’s pharmaceutical output. No specific deadline
was defined to complete Brazil’s support, but extensions
of the original 2011 agreement were to be negotiated every
3 years through Official Complementing Agreements
(Ajustes complementares) [36].
The first 3-year cooperation agreement was signed in
2011, and is due to be renovated through 2017. Infrastruc-
ture work was finalised in 2012, and manufacturing of aFigure 2 Timelines of the implementation of the factory project.few pharmaceutical compounds (Nevirapine, Lamivudine,
Captopril, Hydrochlorothiazide and Propranolol) was
started in 2013 (see Figure 2).
The factory is not expected to have capacity to pro-
duce active pharmaceutical ingredients (APIs) – so-
called “primary manufacturing” -, but 21 generic drugs
are planned to be produced through mixing raw mate-
rials and packaging – secondary and tertiary production
[5]. These include 6 ARVs, 5 hypertension drugs and a
list of other drugs specifically requested by the MISAU
(see full list in Table 1). A laboratory for the control of
medicine quality has been already established, equipped
to test drugs for efficacy and safety. When fully func-
tional, the laboratory will be capable of providing infor-
mation on the quality of all the drugs imported into the
country and of contributing to the development of new
drug testing methodologies.
Although widely known as ‘the Brazilian ARV factory’
because of its original focus on supporting the national
AIDS fight and the perceived complexity of ARV pro-
duction in resource-poor settings, in 2011 the enterprise
was officially registered as ‘Mozambique Pharmaceutical
Ltd’ (Sociedade Moçambicana de Medicamentos, SMM)
as it plans to extend production beyond antiretroviral
Table 1 List of pharmaceutical compounds to be
produced by SMM
API Presentation Type of drug
Amoxicilline 500 mg caps gel Antibiotic
beta-lactam
Captopryl 50 mg cmps Antihypertensive
Captopryl 25 mg cmps Antihypertensive
Captopryl 12.5 mg cmps Antihypertensive
Cetoconazol 200 mg cmps Antimycotic
Diazepam 10 mg cmps Anxiolytic
Estavudine 40 mg cps gel Antiretroviral
Fluconazol 100 mg cps gel Antimycotic
Folic acid 5 mg cmp Anti anaemic
Glibenclamide 5 mg cmps Antidiabetic
Haloperidol 5 mg cmps Neuroplectic
Hydrochlorthiazide 25 mg cmps Diuretic
Lamivudine 150 mg cmp Antiviral
Lamivudine + Zidovudine (150 + 300) mg cmp Antiretroviral
Lamivudine + Zidovudine +
Nevirapine (adults)
(150 + 300 + 200)
mg cmp
Antiretroviral
Lamivudine + Zidovudine +
Nevirapine (pediatric)
(30 + 60 + 50)
mg cmp
Antiretroviral
Metyldopa 500 mg cmps Antihypertensive
Metronidazol 250 mg cmps Anti infective
Nevirapine 200 mg cmp Antiretroviral
Oseltamvir 75mgcps gel Antiviral
Propranolol 40 mg cmps Antihypertensive
Propranolol 20 mg cps gel Antiretroviral
Propranolol 30 mg cps gel Antiretroviral
Ribavirine 250 mg cps Antiretroviral
Zidovudine 100 mg cps Antiretroviral
Source: SMM Limited (2013).
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State Assets Management Institute (IGEPE), but the chair
of its administrative board is appointed by MISAU, as is
the executive director of the factory. Beside the occasional
Brazilian technical assistance necessary for training and
setting up the operation, two key full time Farmanguinhos
consultants have been appointed for the next two years
with the objective of steering the factory towards sustain-
able production and WHO Quality Certification [36].
So far the factory’s overall setup costs have been esti-
mated at USD 34.6 million, excluding the technical as-
sistance by Brazilian officials who are setting up the
operation, which Brazil does not report as cooperation
expenditures but is believed to be substantial [35]. Al-
though the Brazilian Government funded the majority of
the project’s expenditures, the Government of Mozambique
contributed approximately USD 8.5 million for buying upland and existing infrastructures for the establishment
of the new factory. A direct donation of USD 4.5 mil-
lion from VALE, a Brazilian mining company operating
in Mozambique, supported management costs and the
purchase of the old infrastructures.
The factory’s business plan predicted wholesale selling
price levels at which the factory would break even, on
the basis of the cost structure model used for the pro-
duction of ARVs in Brazil’s state pharmaceutical factories
adapted to the Mozambican context [37]. Although
SMM drugs face higher API costs, because of Mozambique’s
burdensome import duties, as well as high maintenance
costs, according to the factory’s business plan these will be
offset by lower capital costs and smaller operating profits,
typical of a state-subsidised company [38]. The table
below shows that SMM’s ARVs unit prices compare well
with those currently procured and imported by inter-
national health organizations in Mozambique and with
the reference prices reported by the Management Science
for Health International Price Indicator guide (Table 2).
At the time of writing most of the original objectives
of the factory’s project have been achieved: infrastructure
works have been completed and equipment installed; 7
out of 21 technological dossiers for the production of
specific pharmaceuticals have been transferred; all the
permanent staff (80) bar the administrative and technical
directors have been recruited and trained; production lines
of intravenous solutions and 5 drugs have been started.
Under the assumption that an extension to Brazilian sup-
port is agreed until 2017, the factory is expected to break
even in 2016 [39].
This is the only pharmaceutical factory existing in
Mozambique, and the first publicly owned in the Sub-
Saharan region, although established private factories
have existed for decades in South Africa, Zimbabwe and
Tanzania. However, a number of issues still need to be
addressed to establish the factory’s production on a sus-
tainable path. While local skills shortages were overcome
though training Mozambican staff in Brazil, the hand
over of certain management positions and functions is
still on going. Because of Mozambique’s poor industrial
environment, all the raw materials and maintenance ser-
vices for pharmaceutical transformation had to be pro-
cured abroad (mostly in South Africa, China, India and
Brazil), but steady supply channels will have to be estab-
lished before the likely end of Brazil’s support in 2017.
Before such date international quality certifications will
have to be acquired, without which there would be no
access to international bids and the regional market.
Given that the vast majority of the Mozambique’s public
drug bill is paid by international grants and donations,
whose pharmaceuticals are procured through large inter-
national tenders, it is unclear how the MISAU will find
the necessary funding to absorb the factory’s output.
Table 2 Unit price for selected ARVs as calculated by SMM’s business plan, by source (2013 USD)
Product SMM1 CHAI2 WHO2 PEPFAR2 MSH3
Min Max Min Max Min Max
3TC - Lamivudine 150 mg (60 cps) 0.045 0.044 0.040 0.050 0.051 1.625 0.0408 0.1578
NVP - Nevirapine 150 mg (60 cps) 0.049 0.050 0.040 0.050 0.057 1.928 0.0452 0.2596
AZT - Zidovudine + NVP + 3TC (300 + 200 + 150 mg) (60 cps) 0.205 0.186 0.180 0.200 0.286 0.971 0.1488 0.3006
AZT - Zidovudine + 3TC (300 + 150 mg) (60 cps) 0.168 0.146 0.130 0.150 0.158 2.905 0.1446 0.4629
Source: 1SMM Financial Department; 2CMAM; 3Management Science for Health International Price indicator guide.
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to implement its AIDS treatment strategy was one of the
original objectives of the factory project. However, unlike
the situation in Brazil, where the Ministry of Health is in
charge of public pharmaceutical production, a public busi-
ness institution – IGEPE – has been put at the helm
of the state’s pharmaceutical plant in Mozambique, and
MISAU’s involvement so far has been mostly limited to a
supervisory role. As no mention of the factory is made in
MISAU’s health policy documents, it is unclear what the
GoM’s long-term plans are for the factory, including
whether and in what fashion it may consider engaging in a
partnership with international pharmaceutical companies
to run the factory once Brazil’s support comes to an end.
Summary
The ARV factory in Mozambique is an example of South-
South cooperation in the health sector, as well as of state-
driven local production of pharmaceuticals. As the factory
has not started full production yet, it is difficult to accur-
ately predict its impact on Mozambique’s pharmaceutical
sector and ultimately, on its population’s access to drugs.
However, a number of considerations can be drawn from
this experience.
The factory represents a health sector investment of
USD 34.6 million over 10 years; this represents a fairly
minor cooperation project in a country that according to
some estimates [40] received in excess of USD 2.5 billion
of development assistance for health between 2002 and
2010. However, the Maputo factory’s potential ramifica-
tions for the Mozambican pharmaceutical market and ac-
cess to ART are likely to be substantial, not least because
of the interest the project has attracted in the media [41].
It seems fair to conclude that Brazil has managed to punch
above the weight of its limited funds for health develop-
ment cooperation with Africa by drawing from its domes-
tic experience and expertise, and by showing a willingness
to venture into unchartered cooperation modalities that
are considered unorthodox by official development co-
operation agencies.
The Maputo factory experience also suggests that local
factories may be able to produce at competitive prices
with the help of government and international cooper-
ation subsidies. It also appears to show that a publiclyowned pharmaceutical factory in LMIC would be able to
generate information-related public benefits that are
often ignored by the traditional arguments around local
production of medicines; a public factory may enable
government to regulate by participating in the pharma-
ceutical market, feeding back vital information on drug
efficacy, costs and players’ conduct [42,43]. Traditional
setbacks in development project implementation such as
changes in governments, scarcity of skills, capital, ser-
vices and raw materials in the local market have been
overcome by, respectively, training staff in Brazil, pro-
curing products and services from neighbouring coun-
tries, and resorting to public-private support for extra
funds.
Sustainability of the factory after the likely end of Brazil’s
support in 2017 remains an issue. Brazil’s original object-
ive was to set up a pharmaceutical factory under the direct
control of MISAU to help implementing its pharmaceut-
ical policy, the way public enterprises are set up in Brazil.
However, the GoM’s appointment of IGEPE, together with
the conspicuous absence of references to the factory in
MISAU’s policy documents, seem to signal a more pro-
nounced interest in the factory’s contribution to the coun-
try’s industrial asset, rather than to its public health goals.
The GoM will have to decide sooner rather than later
whether it is still in its interest to keep the factory as a
public enterprise, or to privatize it in the way similar expe-
riences developed in Uganda and South Africa [44,45].
The lack of flexibility of the international drugs financing
environment also appears to be a key limiting factor for
the development of local production of pharmaceuticals
in Mozambique; even if drugs were made available at
competitive prices, the way external funds are currently
regulated would stand on the way of procuring locally
produced drugs. Furthermore, free internationally pro-
cured ARVs end up crowding out the local private sector,
which is traditionally a key customer for locally produced
goods [46,47].
Crucially, the setbacks experienced so far in securing the
factory’s financial, technical and political sustainability ex-
pose Brazil’s lack of familiarity with the complexities of de-
velopment project implementation in a context that is very
different from its own [48]. Many risks have been taken in
this project, from underestimating the impact of
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securing public sector’s drugs purchases, and the conun-
drum of recruiting and retaining skilled personnel in Africa
[27]. As things stand, it is still unclear whether the project
will manage to achieve all its original objectives, but if it
does, it will have contributed to pushing the boundaries of
the debates on health aid and on local production of phar-
maceuticals. Judging by the interest that the factory is
attracting worldwide [49], many health policymakers, aca-
demics and aid practitioners are watching this space.
Endnotes
aNamed after the senator who promoted the bill.
bSuch TRIPS flexibilities are defined as: the possibility
to grant third parties the right to produce a patented
drug without consent of the patent holder for public
health emergencies (compulsory licensing); reproducing
drugs under patent for experimental use (experimental
exemption); carrying out all the required tests for drugs
generic production before their patents expire (bolear
exemption); importing lower-price drugs from other
countries without the consent of the patent holder on
the domestic market (parallel import), and; the possibil-
ity for government agencies to intervene and provide
their consent in the patent application process (govern-
ment participation).
cSuch as Saidal in Algeria and Saphad in Tunisia.
dFor example CIPLA and Quality Pharmaceuticals in
Uganda.
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